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Objectives: The emergence of polymyxin resistance threatens to leave clinicians with few options for combat-
ting drug-resistant Acinetobacter baumannii. The objectives of the current investigation were to define the
in vitro emergence of polymyxin resistance and identify a combination regimen capable of eradicating A. bau-
mannii with no apparent drug susceptibilities.
Methods: Two clonally related, paired, A. baumannii isolates collected from a critically ill patient who developed
colistin resistance while receiving colistin methanesulfonate in a clinical population pharmacokinetic study were
evaluated: an A. baumannii isolate collected before (03-149.1, polymyxin-susceptible, MIC 0.5 mg/L) and an iso-
late collected after (03-149.2, polymyxin-resistant, MIC 32 mg/L, carbapenem-resistant, ampicillin/sulbactam-
resistant). Using the patient’s unique pharmacokinetics, the patient’s actual regimen received in the clinic was
recreated in a hollow-fibre infection model (HFIM) to track the emergence of polymyxin resistance against
03-149.1. A subsequent HFIM challenged the pan-resistant 03-149.2 isolate against polymyxin B, meropenem
and ampicillin/sulbactam alone and in two-drug and three-drug combinations.
Results: Despite achieving colistin steady-state targets of an AUC0–24.60 mgh/L and Cavg of.2.5 mg/L, colistin
population analysis profiles confirmed the clinical development of polymyxin resistance. During the simulation
of the patient’s colistin regimen in the HFIM, no killing was achieved in the HFIM and amplification of polymyxin
resistance was observed by 96 h. Against the polymyxin-resistant isolate, the triple combination of polymyxin B,
meropenem and ampicillin/sulbactam eradicated the A. baumannii by 96 h in the HFIM, whereas monotherapies
and double combinations resulted in regrowth.
Conclusions: To combat polymyxin-resistant A. baumannii, the triple combination of polymyxin B, meropenem
and ampicillin/sulbactam holds great promise.
Introduction
Acinetobacter baumannii has emerged as a troubling nosocomial
pathogen, largely due to its ability to acquire resistance mechan-
isms against commonly used antimicrobials.1 While carbapenems
were traditionally used as the agents of choice against MDR
A. baumannii, the rising prevalence of carbapenem resistance has
necessitated the use of polymyxin B or colistin (polymyxin E).
However, A. baumannii strains have emerged that display high
levels of resistance to polymyxins through lipid A modification
or complete loss of lipopolysaccharides.2 Even more worrisome
are recent reports of plasmid-mediated polymyxin resistance
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determinants (MCR-1) that are capable of transferring between
Gram-negative species.3
One strategy for overcoming polymyxin resistance is the add-
ition of antimicrobials that individually lack activity against
polymyxin-resistant A. baumannii to create an active polymyxin
combination regimen. Interestingly, a recently published study
found that 19 patients developed colistin-resistant A. baumannii
following treatment with colistin methanesulfonate (CMS).
Subsequent treatment of ventilator-associated pneumonias
(most commonly) using a triple combination of CMS, a carbape-
nem and ampicillin/sulbactam resulted in superior 30 day survival
compared with other antibiotic regimens (P"0.03).4
In the present study, a polymyxin-susceptible isolate collected
prior to a patient’s colistin therapy in an open-label CMS population
pharmacokinetic study and a polymyxin-resistant isolate subse-
quently collected during colistin treatment were used to investi-
gate polymyxin resistance in vitro. First, the polymyxin-susceptible
isolate was exposed to the patient’s clinical antibiotic regimen in a
hollow-fibre infection model (HFIM) to mirror the in vivo evolution
of polymyxin resistance. The polymyxin-resistant isolate collected
from the patient was then used in a 14 day HFIM to profile the de-
tailed pharmacodynamics and resistance suppression of a poly-
myxin B, meropenem and ampicillin/sulbactam triple combination
against anA. baumannii strain resistant to all the investigated anti-
microbials. Polymyxin B was selected over colistin for evaluation in
the HFIM because polymyxin B has more favourable pharmacokin-
etics, which include administration of an active moiety and the
lack of renal dose adjustments.5
Methods
Bacterial isolates and clinical data for Patient 149
Two A. baumannii isolates (03-149.1 and 03-149.2) were collected from a
41-year-old patient (Patient 149) with multiple myeloma at the Siriraj
Hospital in Bangkok, Thailand, who received CMS as part of his clinical care
for treatment of pneumonia due to Gram-negative bacillus, as part of an
open-label population pharmacokinetic study on CMS.6 Patient 149 first
presented with pneumonia due to A. baumannii; the polymyxin-susceptible
isolate 03-149.1 was collected from an endotracheal aspirate and CMS
therapy was subsequently initiated on day 1 and consisted of a 300 mg co-
listin base activity loading dose with a maintenance regimen of 75 mg
every 12 h. On day 4, the patient’s CMS dose escalated to 150 mg every
12 h, and 500 mg of meropenem every 12 h was started. On day 5, a
second A. baumannii isolate was then collected from an endotracheal as-
pirate that was polymyxin resistant (03-149.2) and clonally identical to
the first polymyxin-susceptible isolate (03-149.1) on PFGE. Figure 1(a) dis-
plays the timeline of antibiotic administration and isolates collected from
Patient 149.
Antibiotics and susceptibility testing
Analytical grade polymyxin B was purchased from Sigma–Aldrich (St Louis,
MO, USA). Fresh stock solutions of polymyxin B were prepared immediately
prior to each experiment. Cation-adjusted Mueller–Hinton broth (CAMHB)
(Difco, Detroit, MI, USA) supplemented with calcium (25 mg/L) and magne-
sium (12.5 mg/L) was used as the growth medium. MIC values were deter-
mined in quadruplicate according to the CLSI guidelines. Isolate 03-149.2
was resistant to all antibiotics tested, including colistin and polymyxin B
(MICs 32 mg/L each), meropenem (MIC 64 mg/L) and ampicillin/sulbactam
(MIC 32/16 mg/L), whereas 03-149.1 was susceptible to colistin and
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Figure 1. (a) Patient 149’s treatment course involving CMS regimens
combined with meropenem. Two endotracheal isolates of A. baumannii
(AB) were collected from Patient 149. The first isolate was collected prior
to colistin therapy and was polymyxin susceptible (03-149.1), whereas
the second isolate was collected during colistin treatment and was poly-
myxin resistant (03-149.2). (b) Patient 149’s measured CMS and colistin
concentrations are shown as filled circles, whereas lines represent con-
centrations predicted by a population pharmacokinetic model in the
CMS/colistin clinical study by Garonzik et al.6 To completely simulate
Patient 149’s colistin pharmacokinetics and meropenem regimen (see
panel a), a subsequent HFIM was used to recapitulate the patient’s colis-
tin profile against the polymyxin-susceptible 03-149.1 and the total bac-
terial population quantified in the HFIM is shown. (c) The A. baumannii
collected throughout the HFIM were investigated using colistin PAPs to
observe the stepwise increase in colistin resistance during in vitro colistin
exposure to the polymyxin-susceptible (03-149.1) isolate, which was
compared with the in vivo derived colistin-resistance isolate (03-149.2),
which occurred in Patient 149. q8h, every 8 h; q12h, every 12 h.
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polymyxin B (MICs 0.5 mg/L each), but resistant to meropenem (MIC
64 mg/L) and ampicillin/sulbactam (MIC 32/16 mg/L).
Population analysis profiles (PAPs)
To compare the relative susceptibilities of the two clinical isolates,
108 cfu/mL inocula of the polymyxin-susceptible (03-149.1) and
polymyxin-resistant (03-149.2) isolates were used to determine colistin,
polymyxin B, meropenem and ampicillin/sulbactam PAPs. In brief, serial di-
lutions of the 108 cfu/mL inocula were performed and then subsequently
plated onto Mueller–Hinton agar (MHA) containing 0–128 mg/L drug.
Following 48 h of incubation at 37C, colonies were enumerated to quantify
populations with varying degrees of antibiotic susceptibility.
Simulating Patient 149’s colistin regimen in the HFIM
An HFIM was used to simulate the exact clinical regimen that Patient 149
received by using a population pharmacokinetic model to generate the pa-
tient’s colistin profile from day 0 to day 5 of clinical treatment. Using Patient
149’s specific half-life of 19 h, the colistin profile of a 300 mg CMS loading
dose followed by a CMS maintenance dose of 75 mg every 12 h that esca-
lated to 150 mg every 12 h on day 4 was simulated (colistin
fCmax"3.6 mg/L on day 1, fCmax"1.8 mg/L on day 3 and fCmax"2.3 mg/L
on day 5). On day 4 of the HFIM, 500 mg of meropenem every 12 h was
simulated using a 2 h half-life and fCmax of 23 mg/L. Beginning with a start-
ing inoculum of 108 cfu/mL 03-149.1, samples were periodically withdrawn
from the HFIM and used for viable cell counts on MHA, as well as colistin
PAPs on MHA containing 0–128 mg/L colistin.
Antibiotic combinations against polymyxin-resistant,
carbapenem-resistant 03-149.2 in the HFIM
To identify a combination of antibiotics that maintains activity against the
Patient 149’s polymyxin-resistant strain (03-149.2), HFIM experiments
were conducted over 14 days as described previously.7 Polymyxin B was
utilized instead of colistin due to the superior kinetics of polymyxin B, which
allow rapid target attainment.5 Meropenem and ampicillin/sulbactam
were also investigated due to the reported success of a polymyxin, merope-
nem and ampicillin/sulbactam combination against polymyxin-resistant
A. baumannii.4 On the day of each experiment, overnight cultures of
03-149.2 were used to achieve a 108 cfu/mL inoculum in CAMHB. Bacterial
samples were collected at 0, 1, 2, 3, 4, 6, 24, 26, 28, 30, 48, 50, 52, 54, 72,
74, 76, 78, 96, 144, 192, 240, 288 and 336 h for viable cell counting. As poly-
myxin hetero-resistance has been frequently reported in A. baumannii,8
real-time polymyxin PAPs were conducted every 24–48 h using 0.5, 1, 2
and 10 mg/L polymyxin B.
A dose-optimized polymyxin B regimen was simulated based on a re-
cent population pharmacokinetics study in 24 adult patients that received
physician-selected, intravenous polymyxin B regimens ranging from 0.45
to 3.38 mg/kg/day.5,9 The simulated polymyxin B half-life was 8 h and un-
bound drug concentrations were calculated using a protein binding level
of 58%. The concentration–time profiles of an FDA approved dose of mero-
penem10 and a high dose of ampicillin/sulbactam that has been utilized
in patients11 were also simulated in the HFIM. Both meropenem and
ampicillin/sulbactam were administered as 3 h prolonged infusions with a
1.5 h half-life. During combination regimens, the half-lives of multiple
agents were maintained as described previously.12 The following regimens
were simulated in the HFIM: alone; as double combinations (polymyxin
B!meropenem, polymyxin B!ampicillin/sulbactam and merope-
nem!ampicillin/sulbactam); and as a triple combination of all three
agents [3.33 mg/kg polymyxin B at time 0 h (fCmax"3.61 mg/L) then
1.43 mg/kg every 12 h (fCmax"2.41 mg/L, fAUCss"35.9 mgh/L, where ss
means steady-state), 2 g of meropenem every 8 h (fCmax"54.8 mg/L) and
8 g/4 g of ampicillin/sulbactam every 8 h (fCmax"132/70.2 mg/L)].
Pharmacokinetics
Polymyxin B concentrations were determined by an LC–single quadrupole
MS (LC–MS) method13 with good reproducibility (coefficients of variation
10%) and accuracy (observed concentrations were 10.0% from target
concentrations). Meropenem concentrations were quantified by LC–MS/MS
using an Agilent 1200 and Agilent 6430 (Santa Clara, CA, USA). The merope-
nem calibration curve was linear, with R2 .0.999 and good reproducibility
(coefficient of variation 3.57%) and accuracy (99.7%–109.4%). The
limit of quantification was 0.05 mg/L.14 Sulbactam concentrations were
analysed on a triple quadrupole LC–MS/MS (Agilent 6460 series).
Chromatographic separation used an Agilent XDB-C18 column (particle size
1.8 lm; 50%4.6 mm) with a gradient elution (water and acetonitrile, both
containing 0.1% formic acid). Mass transitions were m/z 234–124 for
sulbactam.
Results
The PAPs for isolates 03-149.1 and 03-149.2 are shown for colistin,
polymyxin B, meropenem and ampicillin/sulbactam in Figure S1
(available as Supplementary data at JAC Online). Although only
minor differences between isolates were noted for subpopulations
with reduced susceptibilities to meropenem and ampicillin/sulbac-
tam, 03-149.2 contained subpopulations capable of growing on
0.5, 1 and 2 mg/L colistin that were over 103, 105 and 101.5 times
more abundant than 03-149.1. For each isolate, colistin and poly-
myxin B PAPs were relatively similar.
The pharmacokinetic profiles of Patient 149’s CMS and colistin
concentrations were constructed by applying a population phar-
macokinetic model to plasma samples taken before and after the
eighth dose of CMS (Figure 1b).6 Following Patient 149’s seventh
dose of CMS, a colistin trough of 1.58 mg/L was recorded and a co-
listin peak concentration of 2.67 mg/L was observed after the
eighth CMS dose (model-projected AUCss 62.5 mgh/L). To track
the development of polymyxin resistance in vitro, the isolate taken
from Patient 149 prior to CMS treatment (03-149.1) was exposed
to a simulation of Patient 149’s colistin regimen in an HFIM. The
simulated colistin regimen was incapable of reducing bacterial
counts in the HFIM, with a total population that exceeded
1010 cfu/mL by 24 h. The addition of meropenem on the fourth
day of treatment was also incapable of conferring additional killing
over colistin alone. Colistin PAPs conducted on samples taken from
the HFIM revealed that the emergence of colistin resistance in the
HFIM was delayed, with counts on MHA imbued with .1 mg/L co-
listin remaining below 103 cfu/mL by 72 h, followed by growth on
MHA containing 8 mg/L colistin that exceeded 105 cfu/mL at
96 h. The in vitro-derived resistance profiles generated from the
HFIM versus the in vivo-derived resistance profile in Patient 149 are
strikingly similar (Figure 1c).
Clinical polymyxin B, meropenem and ampicillin/sulbactam
combinations were simulated in 14 day HFIMs against 03-149.2 to
assess the combinatorial pharmacodynamics of agents that lack
individual activity against resistantA. baumannii isolates (Figure 2).
When used alone, none of the antimicrobials was able to cause a
noticeable reduction in bacterial counts (Figure 2b–d). Similarly,
ampicillin/sulbactam in combination with either polymyxin B or
meropenem was unable to achieve.0.5 log10 cfu/mL reduction in
total counts (Figure 2f and g). In contrast, the polymyxin B and
meropenem combination reduced counts by 4.2 log10 cfu/mL at
6 h, followed by gradual regrowth over 66 h until observed counts
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Figure 2. Clinical regimens of polymyxin B, meropenem and ampicillin/sulbactam were simulated in 14 day HFIMs against an A. baumannii isolate
(03-149.2) resistant to all three agents from Patient 149. MICs: colistin and polymyxin B, 32 mg/L each; meropenem, 64 mg/L; and ampicillin/sulbac-
tam, 32/16 mg/L. Polymyxin B, meropenem and ampicillin/sulbactam were investigated alone (b–d), as double combinations (e–g) and as a triple
combination of all three agents (h). The simulated antibiotic regimens consisted of 3.33 mg/kg polymyxin B at time 0 h (fCmax" 3.61 mg/L) then
1.43 mg/kg every 12 h (fCmax"2.41 mg/L), 2 g of meropenem every 8 h (fCmax"54.8 mg/L) and 8 g/4 g of ampicillin/sulbactam every 8 h
(fCmax"132/70.2 mg/L). Circles represent the total population of A. baumannii plated on drug-free agar, whereas the other symbols correspond to
A. baumannii that grew on agar containing polymyxin B (0.5, 1, 2 and 10 mg/L).
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were.109 cfu/mL by 72 h (Figure 2e). The combination of all three
agents achieved a similar 4.2 log10 cfu/mL reduction at 6 h, but
the bacterial burden continued to decline until no viable cells were
detected, beginning at 96 h (Figure 2h). Surprisingly, proliferation
of polymyxin-resistant subpopulations was only observed during
the polymyxin B and meropenem combination with 103 cfu/mL
(0.001% of initial population) of A. baumannii growing on 10 mg/L
polymyxin B at baseline and.108 cfu/mL (10% of final population)
being detected at 336 h.
Discussion
Strains of A. baumannii are emerging that are capable of mounting
resistance mechanisms against nearly all of the antimicrobials
available in the global armamentarium. Here, we profile the time
course of polymyxin resistance during exposure to CMS of a patient
who received this antimicrobial together with meropenem in an
open-label population pharmacokinetic study. Despite achieving
the colistin steady-state targets proposed by Garonzik et al.6 and
Nation et al.15 of an AUC0–24 .60 mgh/L and Cavg of .2.5 mg/L,
the emergence of polymyxin resistance was confirmed by colistin
PAPs of 03-149.1 and 03-149.2. Previous metabolomic and struc-
tural analyses of Patient 149’s polymyxin-resistant isolate (03-
149.2) identified the modification of lipid A with phosphoethanol-
amine,16 suggesting that polymyxin resistance in 03-149.2 is
mechanistically similar to resistance conferred by the MCR-1 phos-
phoethanolamine transferase plasmid.3 However, an important
limitation of the present study is the simulation of colistin plasma
concentrations, which likely resulted in much greater colistin ex-
posure than would be expected for peripheral tissues such as the
lungs. Due to the uncertainty of how to optimally dose agents in
polymyxin combinations at the time of the clinical pharmacoki-
netic study, Patient 149 also received a non-traditional adjunctive
meropenem dose of 500 mg every 12 h; however, a recent investi-
gation has suggested that high carbapenem exposure is necessary
to prevent the emergence of resistance.14
In agreement with the clinical observation made by Qureshi
et al.4 that colistin exposure may result in colistin-resistant
A. baumannii strains, exposure of a colistin-susceptible A. bau-
mannii isolate (03-149.1) to a clinical colistin regimen in the
HFIM resulted in the gradual emergence of polymyxin resist-
ance. The in vitro HFIM-generated profiles demonstrated a
heterogeneously resistant profile that was similar to that of the
03-149.2 isolate after in vivo colistin exposure in Patient 149.
The common bacterial signatures of polymyxin resistance
derived from the HFIM and that in the actual patient are striking,
providing new insight into the emergence of polymyxin resist-
ance. Although the amplification of polymyxin resistance was
most pronounced after a low-dose meropenem regimen was
initiated, the causality of the sudden shift in resistant subpopu-
lations remains unknown; however, the polymyxin B and mero-
penem combination was also the only combination that
demonstrated the proliferation of polymyxin resistance against
03-149.2, suggesting that concomitant carbapenem use that
fails to achieve microbiological eradication may exacerbate the
emergence of polymyxin resistance. The simulated colistin and
meropenem regimens were unable to achieve killing, due to the
development of colistin resistance by day 4. Two randomized
clinical trials are currently evaluating colistin monotherapy ver-
sus colistin in combination with meropenem to better deter-
mine the potential advantages of combination therapy in
Gram-negative bacteria with nominal polymyxin susceptibility
(NCT01732250 and NCT01597973).
Against polymyxin-resistant A. baumannii, the encouraging
performance of the triple combination of polymyxin B, merope-
nem and ampicillin/sulbactam is consistent with a recent study
that investigated the treatment of colistin-resistant A. baumannii
infections.4 Out of 17 patients, 7 received triple therapy with ampi-
cillin/sulbactam, a carbapenem and colistin, whereas the 10 other
patients received either ampicillin/sulbactam monotherapy, a
double combination of a carbapenem and colistin, or a triple com-
bination utilizing colistin, tigecycline and either rifampicin or ampi-
cillin/sulbactam. All of the patients receiving the triple combination
of colistin, a carbapenem and ampicillin/sulbactam survived for at
least 30 days following their diagnoses, whereas 6 out of 10 pa-
tients receiving the other treatments died (P"0.03). The authors
concluded that the promising results of their study require further
validation.4 In the current study, the triple combination was the
only regimen capable of eradicating the polymyxin-resistant
A. baumannii isolate, further supporting the clinical utility of the
combination. Considering the lack of an immune component to
the in vitro HFIM, in vivo systems that benefit from granulocyte-
mediated bacterial clearance may have an increased likeliness of
bacterial eradication during combination therapy.
In conclusion, the triple combination of polymyxin B, merope-
nem and ampicillin/sulbactam demonstrated sustained bactericidal
activity against a polymyxin-resistant A. baumannii isolate in a
14 day HFIM. It is also noteworthy that the polymyxin B plus mero-
penem combination amplified polymyxin B resistance in 03-149.2
despite high levels of resistance at baseline, which highlights the risk
of being too conservative with the design of combination regimens.
Considering the high inoculum, these results encouragingly suggest
that polymyxin-resistant A. baumannii responsible for high-burden
infections may be treated with agents to which the organism is
nominally resistant, as indicated by MIC testing. Due to the intrinsic
activity of sulbactam against A. baumannii, the triple combination
pursued in the current study may not have applications outside of
Acinetobacter species. Fortunately, new b-lactam/b-lactamase
combinations such as ceftolozane/tazobactam and ceftazidime/avi-
bactam may be viable options for some strains of MDR Klebsiella
pneumoniae and Pseudomonas aeruginosa, whereas the introduc-
tion of new antimicrobials may eventually expand the number of
therapeutic options againstA. baumannii.
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